DelveInsight’s pharmaceuticals report, “Velmetia - Drug Insights, 2014” provides Velmetia marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent details, route of synthesis, competitive landscape, and analysis of sales performance during the forecast period (2011-2015). The report also includes SWOT analysis for the drug. This report is built using data and information sourced from DelveInsight proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by DelveInsight team of industry experts.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug.
A review of the Velmetia based on information derived from company and industry-specific sources
Coverage of the Marketed data of the Velmetia on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Schizophrenia drugs with location details
Patent Expiry Timeline and Exclusivity Details
Route of Synthesis of the API
Global Forecasted Sales Figure from 2011-2015
Qualitative and quantitative assessment of market space
Reasons to buy
Evaluate the marketing status and exclusivity details of Velmetia to exploit opportunities for generic drug development opportunities.
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Velmetia.
API intelligence over Velmetia and gaining primary intelligence over Active Ingredients manufacturers across the globe.
Understanding the chemical route of synthesis of Velmetia.
Uncovering opportunities in the rapidly growing the US market
Stay ahead of competition by understanding the changing competitive landscape
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
Obtain sales forecast for currently marketed drug for 2011-2015
Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.